Transcranial sonography in carriers of Gaucher disease

Fatemeh Omrani1, Shahla Ansari-Damavandi2, Babak Zamani3, Zahra Omrani1, Nahid Mohammadzade1, Sadra Rohani1, Mohammad Rohani1

1 Department of Neurology, Hazrat-e-Rasool Hospital, Iran University of Medical Sciences, Tehran, Iran
2 Department of Pediatric Hematology, Ali Asghar Children’s Hospital, Iran University of Medical Sciences, Tehran, Iran
3 Department of Neurology, Firouzgar Hospital, Iran University of Medical Sciences, Tehran, Iran

Keywords
Transcranial Sonography; Gaucher Disease; Glucocerebrosidase; Parkinson’s Disease; Substantia Nigra

Conclusion: Increased SN echogenicity and increased third ventricle diameter in GBA mutation carriers may be caused by alterations in iron metabolism with reference to their genetic status.

Introduction
Transcranial sonography (TCS) of brain parenchyma is a useful technique in evaluating movement disorders. About 90% of patients with idiopathic Parkinson’s disease (PD) show increased echogenicity of substantia nigra (SN).1-3 SN hyperechogenicity is also demonstrated in genetic forms of PD, including the ones with mutation in Parkin (PARK2), phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1 or PARK6), leucine-rich repeat kinase 2 (LRRK2 or PARK8), and glucocerebrosidase (GBA).1,2 The degree of SN hyperechogenicity in genetic forms resembles those of sporadic ones.1,2 Heterozygous GBA mutations have been known as the most common genetic risk factor for PD.4,5 PD patients with this mutation clinically looks like patients without this mutation, except for earlier disease onset and more cognitive impairment in GBA mutation carriers.4 It should be mentioned that not all the GBA mutation carriers are neurologically symptomatic.1,4 On the
other hand, non-manifesting carriers may show signs of PD later on; therefore, hyperechogenicity of SN can be a helpful marker in detecting preclinical phase of disease.\textsuperscript{1,6}

Moreover, measuring diameter of the third ventricle (DTV) with TCS has emerged as a marker of brain atrophy and disease progression in PD.\textsuperscript{7}

The goal of this study was to compare maximal area of SN hyperechogenicity (aSN\textsubscript{max}) and third ventricle diameter between GBA carriers and healthy controls.

**Materials and Methods**

Twenty-six GBA mutation carriers were collected from hematology department of a children’s hospital following ethical approval. We chose the carrier group from the parents of genetically-proved patients with Gaucher disease. Twenty-six healthy controls without neurological disease or a family history of PD were also recruited.

All the subjects were neurologically examined including mini-mental status examination (MMSE) and checking for the symptoms of PD (i.e. tremor, rigidity, and hypokinesia). Demographic data including age, sex, familial history of PD in first degree relatives, and smoking history (more than five pack years) were collected using a questionnaire. Both the case and control groups were given information about TCS prior to the test. The authors were committed to the declaration of Helsinki and all the patients signed consent forms.

All fifty-two subjects underwent TCS using the Sonos 5500 ultrasound system (Sonosite) equipped with a 2.0-2.5 MHz sector transducer (S3 probe). The sonographer was blinded to status of the subjects. TCS was done through right and left temporal bone windows with a penetration depth of 14-16 cm. SN echogenicity of each side was measured via ipsilateral temporal window (Figure 1). The larger SN area of each individual was selected for analysis (aSN\textsubscript{max}). The distance between the inner margins of the third ventricle was considered as diameter of the third ventricle (DTV).

We used SPSS software (version 20, IBM Corporation, Armonk, NY) for statistical analysis. For descriptive analysis, we measured mean and standard deviation, and for analytical part, we used parametric and non-parametric tests, independent sample t and one-way ANOVA tests.

**Results**

The mean age of GBA mutation carriers was 35.57 ± 6.92 years, and the control was 34.92 ± 10.14 years.

The mean aSN\textsubscript{max} and the mean diameter of third ventricle were significantly different between the two groups (Figure 2). Mean MMSE score was 29.80 ± 0.56 and 30.00 ± 0.00 in case and control groups, respectively (Table 1).

19.23% of cases had a history of PD in their first-degree relatives, and 26.92% were smokers. According to non-parametric independent sample t test, aSN\textsubscript{max} had statistical difference between the case and control groups (P < 0.001). Mean aSN\textsubscript{max} in control group was significantly lower than case group. Furthermore, third ventricle diameter was statistically higher in GBA mutation carriers (P = 0.013) (Table 1).
Table 1. Demographic and transcranial sonography of Glucocerebrosidase-mutation (GBA-mutation) carriers and healthy controls

| Feature            | GBA mutation carriers (mean ± SD) | Healthy controls (mean ± SD) | P     |
|--------------------|-----------------------------------|-----------------------------|-------|
| Age (year)         | 35.57 ± 6.92                      | 34.92 ± 10.14               | 0.780 |
| aSNmax (cm²)       | 0.31 ± 0.06                       | 0.16 ± 0.04                 | < 0.001|
| DTV (cm)           | 3.83 ± 0.90                       | 3.29 ± 0.56                 | 0.013 |
| MMSE               | 29.80 ± 0.56                      | 30.00 ± 0.00                | 0.090 |

GBA: Glucocerebrosidase; aSNmax: Maximum area of substantia nigra hyperechogenicity; DTV: Diameter of third ventricle; MMSE: Mini-mental status examination; SD: Standard deviation

Discussion

This study revealed that asymptomatic GBA-mutation carriers had greater SN echogenicity rather than healthy controls. This finding supports the idea that GBA mutation causes prominent dopaminergic cell loss in SN. Almost all autopsy proven cases of PD with GBA mutation had shown nigral cell loss. The etiology of Parkinsonism in GBA-mutation carriers is not yet fully understood. Probable mechanisms are reduced α-synuclein degradation, impaired lysosomal function, and lipid metabolism alteration leading to α-synuclein accumulation.

In previous similar studies, such as Barrett, et al. study, GBA mutations were divided into mild and severe mutations based on heterozygous or homozygous subjects. Compared to mild GBA mutations, severe mutations were associated with an increased risk of developing PD and an earlier age of PD onset; but they did not find difference in SN echogenicity between cases with severe and mild mutations.

Since we chose our cases from parents of patients with Gaucher disease, and did not check their genetic status, it was not possible to do such comparison. In addition, we did not assess genetically our control group which was another limitation of our study. The carrier frequency of Gaucher disease in the Ashkenazi Jews is approximately 6%, and is less than 1% in the non-Jewish population. Since none of our cases nor controls were Jews, we expect that this mutation rate is near to zero in our control group.

Diameter of the third ventricle is not broadly assessed with TCS in GBA-mutation carriers. In contrast to the study of Kresojevic, et al. our GBA-mutation carriers demonstrated significantly greater diameter than healthy controls. Since the third ventricle diameter is a marker of brain atrophy and neurodegeneration, GBA-mutation carriers can be prone to a neurodegenerative process; but there are many confounding factors, and we cannot confirm this hypothesis at this point.

Conclusion

This study revealed increased echogenicity of SN and DTV in GBA-mutation carriers. Increased SN echogenicity in GBA-mutation carriers is similar to patients with idiopathic PD which supports the important role of GBA mutation in pathophysiology of PD.

Conflict of Interests

The authors declare no conflict of interest in this study.

Acknowledgments

The authors are grateful to all participants (both groups) for this study.

How to cite this article: Omrani F, Ansari-Damavandi S, Zamani B, Omrani Z, Mohammadzade N, Rohani S, et al. Transcranial sonography in carriers of Gaucher disease. Iran J Neurol 2018; 17(3): 145-8.
Transcranial sonography and glucocerebrosidase mutation

References

1. Bruggemann N, Hagenah J, Stanley K, Klein C, Wang C, Raymond D, et al. Substantia nigra hyperchogenicity with LRRK2 G2019S mutations. Mov Disord 2011; 26(5): 885-8.
2. Walter U, Behnke S, Eyding J, Niehaus L, Postert T, Seidel G, et al. Transcranial brain parenchyma sonography in movement disorders: State of the art. Ultrasound Med Biol 2007; 33(1): 15-25.
3. Favaretto S, Walter U, Baracchini C, Cagnin A. Transcranial sonography in neurodegenerative diseases with cognitive decline. J Alzheimers Dis 2018; 61(1): 29-40.
4. Barrett MJ, Hagenah J, Dhawan V, Peng S, Stanley K, Raymond D, et al. Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease. Parkinsonism Relat Disord 2013; 19(2): 186-91.
5. Kiferle L, Giuntini M, Bonuccelli U, Ceravolo R. Imaging in Glucocerebrosidase-Associated Parkinsonism: Current Status and Implications for Pathophysiology. Neurodegener Dis 2015; 15(5): 271-80.
6. Berg D, Godau J, Riederer P, Gerlach M, Arzberger T. Microglia activation is related to substantia nigra echogenicity. J Neural Transm (Vienna) 2010; 117(11): 1287-92.
7. Kalinderi K, Bostantjopoulou S, Paisan-Ruiz C, Katsarou Z, Hardy J, Fidani L. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci Lett 2009; 452(2): 87-9.
8. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. J Med Genet 2004; 41(12): 937-40.
9. Gan-Or Z, Bar-Shira A, Mirelman A, Gurevich T, Kedmi M, Giladi N, et al. LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease. Neurogenetics 2010; 11(1): 121-5.
10. Kresojevic N, Mijajlovic M, Peric S, Pavlovic A, Svetel M, Jankovic M, et al. Transcranial sonography in patients with Parkinson's disease with glucocerebrosidase mutations. Parkinsonism Relat Disord 2013; 19(4): 431-5.
11. Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinnen L, Lachmann RH, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009; 132(Pt 7): 1783-94.
12. Saunders-Pullman R, Hagenah J, Dhawan V, Stanley K, Pastores G, Sathe S, et al. Gaucher disease ascertained through a Parkinson's center: Imaging and clinical characterization. Mov Disord 2010; 25(10): 1364-72.